Genmab A/S
corporate_fare Company Profile
Genmab A/S (NASDAQ:GMAB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for GMAB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for GMAB spans 6-K.
Recent high-impact activity:
- Genmab 9M Revenue Up 22% to $3,238M; Net Profit Falls to $698M on Merus Costs
- Petosemtamab Combo Cuts Death Risk 50% in Phase 3 Head and Neck Cancer Trial
- Petosemtamab Posts 28.2-Month Survival in Head and Neck Cancer, 75% Response in Colorectal
- Petosemtamab Combo Hits 28.2-Month Median OS in First-Line Head and Neck Cancer
- Phase 3 Win: Rina-S Cuts Ovarian Cancer Progression Risk 71%, Extends Survival
Financial Snapshot
Short Interest & Short Volume
1.24 days to coverFINRA reported short interest of 9,659,086 shares in GMAB as of the October 30, 2026 settlement, a 46.4% increase from the prior period — about 1.2 days to cover at its recent average daily volume. On November 20, 2026, 31.4% of GMAB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
GMAB files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.